2019 Taiwan Society of Lipids and Atherosclerosis expert consensus statement on statin intolerance

Shih Chieh Chien, Po Sheng Chen, Yi Hsiang Huang, Sung Chun Tang, Yi Heng Li*, Hung I. Yeh

*此作品的通信作者

研究成果: Review article同行評審

20 引文 斯高帕斯(Scopus)

摘要

Statin reduces low-density lipoprotein cholesterol and improves clinical outcomes in high risk patients. In general, statin is a safe and well-tolerated medication. However, varieties of adverse effects are reported in some patients and may interfere long-term drug compliance. Statin-associated muscle events and liver function change account for most of these adverse effects. Patients are regarded as statin intolerance if they need to discontinue statin therapy due to these adverse effects. To date, there is no universal standard definition of statin intolerance. But a pragmatic definition of statin intolerance is essential and helpful for clinicians in daily practice. In this article, after expert consensus meetings and literature review, criteria were recommended to identify patients with statin intolerance in Taiwan. The purpose of this statement is to help health care professionals in Taiwan to diagnose and manage individuals who develop muscular and hepatic side effects after statin therapy.

原文English
頁(從 - 到)1385-1392
頁數8
期刊Journal of the Formosan Medical Association
118
發行號10
DOIs
出版狀態Published - 10月 2019

指紋

深入研究「2019 Taiwan Society of Lipids and Atherosclerosis expert consensus statement on statin intolerance」主題。共同形成了獨特的指紋。

引用此